Title : Treatment of patients with MYC rearrangement positive large B-cell lymphoma with R-CHOP plus lenalidomide: results of a multicenter HOVON phase II trial.

Pub. Date : 2020 Dec 1

PMID : 33256379






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Patients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) as compared to patients without MYC rearrangement. Cyclophosphamide MYC proto-oncogene, bHLH transcription factor Homo sapiens
2 Patients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) as compared to patients without MYC rearrangement. Cyclophosphamide MYC proto-oncogene, bHLH transcription factor Homo sapiens
3 Patients with MYC-rearrangement positive large B-cell lymphoma (MYC+ LBCL) have an inferior prognosis following standard first-line therapy with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) as compared to patients without MYC rearrangement. Cyclophosphamide MYC proto-oncogene, bHLH transcription factor Homo sapiens